BackCheckmate Pharmaceuticals Overview

Checkmate Pharmaceuticals Other Assets

Checkmate Pharmaceuticals's other assets is $0.

Get informed when a big investor buys or sells

+ Follow
Other Assets
$0.00

Peer average

Loading

Checkmate Pharmaceuticals Other Assets History

Loading

Checkmate Pharmaceuticals vs. peers: Other Assets Comparison

Loading

Checkmate Pharmaceuticals Other Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Checkmate Pharmaceuticals (CMPI) FAQ

As of the most recent data (March 2022), CMPI shows a other assets of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CMPI's other assets is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Checkmate Pharmaceuticals is outperforming or lagging.

Tracking CMPI's other assets over time shows whether Checkmate Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other assets page, Stockcircle has Checkmate Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other assets (currently $0) with ownership activity and broader fundamentals.

Checkmate Pharmaceuticals's other assets is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.